Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $67K, compared with -$88K a year earlier. Trailing-twelve-month accounts receivables was $183K.

Context

  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $67K or moves back toward the trailing-twelve-month quarterly average of $45.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67K+139.3% QoQ
Last fiscal yearDec 2025
$79K-95.1% YoY
LTMMar 2026
$183K-87.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+176.1%——
1 year-95.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
79K USD
Year-over-year change
-95.1%

Accounts Receivables vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -87.7% is the 3rd highest of 6, against a peer median of -93.9%.
ARTV Competitors
Accounts Receivables for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$5.47M USD-147.5%—12.1%
IFRXInflaRx N.V.LTM Mar 2026€1.95M EUR+3826.6%—6648.5%
STROSutro Biopharma, Inc.LTM Mar 2026$1.08M USD-93.9%-4.6%1.1%
CNTBConnect Biopharma Holdings LimitedFY2025$776K USD+198.4%+512.8%1212.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$183K USD-87.7%——
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 USD———
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
Peer median (excluding ARTV) —-93.9%+254.1%12.1%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.83M)(58.79M)(28.72M)(65.37M)(83.87M)
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
Deferred Income Tax00000
Stock-Based Compensation4.31M6.58M7.05M6.98M6.82M
Change in Working Capital33.41M(3.87M)(28.28M)(325K)(424K)
Accounts Receivables(468K)(57K)(1.23M)1.61M79K
Inventory00000
Accounts Payables(1.24M)190K(408K)519K(760K)
Other Working Capital35.13M(4M)(26.64M)(2.46M)257K
Other Non-Cash Items18.55M4.08M251K1.26M(1.88M)
Operating Cash Flow(15.3M)(50.83M)(47.43M)(55.03M)(76.75M)
Capital Expenditures(1.72M)(6.3M)(3.26M)(642K)(2.59M)
Acquisitions (Net)00000
Purchases of Investments00(49.52M)(176.17M)(44.88M)
Sales of Investments0026.8M56.35M110.87M
Other Investing Activities00000
Investing Cash Flow(1.72M)(6.3M)(25.98M)(120.46M)63.41M
Debt Repayment000(149K)(132K)
Common Stock Issued000166.51M371K
Common Stock Repurchased0(5K)(12K)(4.18M)0
Dividends Paid00000
Other Financing Activities(1.86M)(1.26M)24.4M51K(230K)
Financing Cash Flow152.75M(1.26M)24.39M162.23M9K
Effect of Forex Changes00000
Net Change in Cash135.73M(58.39M)(49.01M)(13.27M)(13.33M)
Free Cash Flow(17.03M)(57.13M)(50.69M)(55.67M)(79.34M)

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.